YD Bio Ltd
YDES Nasdaq Services-Medical Laboratories Financials FY2023–FY2025
What YD Bio Ltd does
No business description yet.
- Legal name
- YD Bio Ltd
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 30, 2026
- Accession · CIK
- 0001213900-26-050282
0002011674
Revenue and margins
YD Bio Ltd had $0.6M of revenue in fiscal 2025, up 16.9% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$8.0M in fiscal 2025, −1,346.6% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
YD Bio Ltd returned — to shareholders in fiscal 2025. The diluted share count rose 3.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably YD Bio Ltd can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $0.1M | $3.1M | $6.0M |
| Debt incl. finance leases | — | — | $0.0M |
| Interest coverage | −4.7x | −1,827.4x | — |
| Current ratio | — | 13.2x | 5.9x |
| Quick ratio | — | 13.0x | 4.7x |
| Total assets | — | $6.9M | $13.8M |
| Total liabilities | — | $0.3M | $16.6M |
| Shareholders' equity | $0.0M | $6.6M | −$2.9M |
| Net debt (− = net cash) | — | — | −$6.0M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | — | ✕ |
| Cash from operations exceeds net income | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | — | ✕ |
| Share count didn't rise | — | ✓ | ✕ |
| Gross margin rose | — | ✕ | ✕ |
| Revenue rose relative to assets | — | — | ✕ |
| F-score | — / 3 | — / 5 | 1 / 8 |
| Accruals ratio | — | −2.8% | −16.6% |
| Altman Z'' | — | 25.97 | −1.35 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $0.4M | $0.5M | $0.6M |
| Gross profit | $0.2M | $0.2M | $0.2M |
| Research and development | — | $0.5M | $1.6M |
| Operating income | −$0.0M | −$1.5M | −$5.3M |
| Interest expense | $0.0M | $0.0M | — |
| Pretax income | $0.0M | −$1.4M | −$8.3M |
| Income tax | $0.0M | $0.0M | −$0.0M |
| Net income | $0.0M | −$1.4M | −$8.3M |
| Diluted EPS | $0.00 | −$0.02 | −$0.12 |
| Diluted shares | 0.06B | 0.06B | 0.07B |
| Cash flow | |||
| Cash from operations | −$0.1M | −$1.2M | −$6.6M |
| Capital expenditure | $0.0M | $0.1M | $1.4M |
| Free cash flow | −$0.1M | −$1.3M | −$8.0M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M |
| Balance sheet | |||
| Cash and short-term investments | $0.1M | $3.1M | $6.0M |
| Total debt | — | — | $0.0M |
| Current assets | — | $3.5M | $9.7M |
| Current liabilities | — | $0.3M | $1.6M |
| Inventory | — | $0.0M | $1.9M |
| Property and equipment, net | — | $0.1M | $0.1M |
| Intangible assets | — | $2.7M | $2.6M |
| Total assets | — | $6.9M | $13.8M |
| Total liabilities | — | $0.3M | $16.6M |
| Shareholders' equity | $0.0M | $6.6M | −$2.9M |
| Margins | |||
| Gross margin | 43.8% | 30.4% | 28.0% |
| Operating margin | −2.8% | −286.4% | −883.3% |
| EBITDA margin | −2.1% | −284.4% | −880.6% |
| Net margin | 3.9% | −276.6% | −1,392.6% |
| FCF margin | −16.0% | −254.2% | −1,346.6% |
| Returns | |||
| Return on capital employed | — | −22.1% | −43.4% |
| Return on equity | 59.1% | −42.7% | −445.1% |
| Return on assets | — | −20.6% | −80.5% |
| Return on tangible equity | 59.1% | −36.1% | — |
| Growth | |||
| Revenue growth | — | 45.8% | 16.9% |
| Net income growth | — | −10,479.4% | — |
| Share count change | — | 0.0% | 3.1% |
| Financial health | |||
| Interest coverage | −4.7x | −1,827.4x | — |
| Current ratio | — | 13.2x | 5.9x |
| Quick ratio | — | 13.0x | 4.7x |
| Capital allocation | |||
| Capex / revenue | 0.1% | 14.7% | 241.3% |
| Quality scores | |||
| Piotroski F-score | — | — | 1.0 |
| Altman Z'' | — | 26.0 | −1.4 |
| Accruals ratio | — | −2.8% | −16.6% |
Source: SEC EDGAR XBRL filings (CIK 0002011674). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.